Sage Mountain Advisors LLC Acquires 4,180 Shares of Bristol Myers Squibb Company $BMY

Sage Mountain Advisors LLC lifted its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 49.2% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 12,670 shares of the biopharmaceutical company’s stock after purchasing an additional 4,180 shares during the period. Sage Mountain Advisors LLC’s holdings in Bristol Myers Squibb were worth $587,000 as of its most recent filing with the SEC.

Other hedge funds have also added to or reduced their stakes in the company. Washington Trust Advisors Inc. boosted its position in Bristol Myers Squibb by 8.9% during the second quarter. Washington Trust Advisors Inc. now owns 4,875 shares of the biopharmaceutical company’s stock valued at $226,000 after buying an additional 400 shares during the period. AlphaQuest LLC lifted its stake in shares of Bristol Myers Squibb by 310.1% in the 2nd quarter. AlphaQuest LLC now owns 18,944 shares of the biopharmaceutical company’s stock valued at $877,000 after acquiring an additional 14,325 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its holdings in Bristol Myers Squibb by 2.1% during the 2nd quarter. Sumitomo Mitsui Trust Group Inc. now owns 5,145,653 shares of the biopharmaceutical company’s stock valued at $238,192,000 after acquiring an additional 103,608 shares during the period. West Michigan Advisors LLC bought a new position in Bristol Myers Squibb during the 2nd quarter worth approximately $370,000. Finally, Harbour Investment Management LLC increased its stake in Bristol Myers Squibb by 2.4% in the 2nd quarter. Harbour Investment Management LLC now owns 30,338 shares of the biopharmaceutical company’s stock worth $1,404,000 after purchasing an additional 718 shares during the period. 76.41% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, EVP David V. Elkins sold 56,000 shares of the business’s stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the sale, the executive vice president owned 167,379 shares in the company, valued at approximately $7,922,048.07. The trade was a 25.07% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.09% of the company’s stock.

Wall Street Analysts Forecast Growth

BMY has been the subject of a number of analyst reports. Morgan Stanley reissued a “hold” rating on shares of Bristol Myers Squibb in a research note on Thursday, July 31st. Dbs Bank raised shares of Bristol Myers Squibb to a “moderate buy” rating in a report on Thursday, October 2nd. Daiwa America downgraded shares of Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 5th. Citigroup reiterated a “neutral” rating on shares of Bristol Myers Squibb in a report on Monday, October 13th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Bristol Myers Squibb in a report on Tuesday, October 14th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and fourteen have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $57.23.

Bristol Myers Squibb Trading Up 0.0%

Shares of BMY opened at $43.84 on Friday. Bristol Myers Squibb Company has a 1-year low of $42.96 and a 1-year high of $63.33. The company has a current ratio of 1.21, a quick ratio of 1.11 and a debt-to-equity ratio of 2.54. The firm’s 50-day moving average price is $45.75 and its 200-day moving average price is $47.10. The firm has a market capitalization of $89.24 billion, a price-to-earnings ratio of 17.68, a PEG ratio of 2.29 and a beta of 0.33.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, topping the consensus estimate of $1.07 by $0.39. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The business had revenue of $12.27 billion during the quarter, compared to analyst estimates of $11.32 billion. During the same period last year, the business posted $2.07 earnings per share. Bristol Myers Squibb’s quarterly revenue was up .6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. Sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Friday, October 3rd will be issued a $0.62 dividend. The ex-dividend date is Friday, October 3rd. This represents a $2.48 dividend on an annualized basis and a yield of 5.7%. Bristol Myers Squibb’s dividend payout ratio is 100.00%.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.